The Healthcare, Life Sciences, and Private Equity teams advised Bruder Consulting & Venture Group (“Bruder” or “BCVG”) on its acquisition by Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting. BCVG is now a department within Dark Horse Consulting (DHC) known as DHC Regenerative Medicine. This acquisition further strengthens DHCG’s patient-centered commitment to accelerating the development and commercialization of biotherapeutics by building out an integrated ecosystem of consulting services.
Bruder Consulting & Venture Group is a full-service strategic advisory firm with expertise in the discovery, development, clinical design, and regulatory approval process of biologics, devices, and combination products in the orthopedic, wound care, and plastic & reconstructive surgery markets. As veterans of product development, BCVG's experts have completed more than 900 projects for over 150 companies around the world, and led or supported more than $2 billion of licensing, merger, and acquisition transactions in the USA and abroad.
The Goodwin team was led by Jim Barrett, Eric Carlson, Jon Berke, Ryan Peloquin, Lexi Brenza, Bradford Smith, Martin Gomez, Kenneth Radcliffe, Jim Mattus, Jacqueline Klosek, Rebecca Kennedy, Daniel Karelitz and Erika Pey, with invaluable assistance from Amanda Fernandes.
For more information on the deal, please read the press release.